Monopar Therapeutics Inc. (MNPR) Investor Relations Documents

Monopar Therapeutics Inc. (MNPR) investor relations documents from the company's IR site: 1 presentation, 24 press releases; latest deck 2026-03-16. Read in-app with summaries. First-party data.

https://d1io3yog0oux5.cloudfront.net/_46c180b00471d92f154cbd1d20ad5d2c/monopartx/db/354/2994/pdf/MNPR+Corporate+Presentation+Mar+2026.pdf: Monopar Therapeutics is a clinical-stage biopharmaceutical company targeting an NDA filing for its lead Wilson Disease candidate, ALXN1840, in 1H 2026.

Investor relations documents — source: company IR site
PublishedTypeDocument
2026-08-19Press releaseMonopar Appoints Jeffrey D. Kent, M.D., as Executive Vice President, Head of Medical Affairs; Announces Two ALXN1840 Pre
2026-08-12Press releaseMonopar Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates
2026-07-22Press releaseMonopar Initiates Rolling NDA Submission for ALXN1840 in Wilson Disease
2026-07-20Press releaseMonopar Advances Launch Readiness with Addition of Veteran Commercial Executive Nicole Sweeny to Board of Directors and
2026-06-30Press releaseMonopar Therapeutics Receives FDA Rare Pediatric Disease Designation for ALXN1840 for the Treatment of Wilson Disease
2026-06-26Press releaseMonopar Presents New Analyses of Phase 3 FoCus Data at EAN 2026 Showing Greater Neurologic and Global Clinical Benefit w
2026-06-01Press releaseMonopar Presents Phase 2 ALXN1840 Data Demonstrating Liver Disease Stabilization and Neurologic Improvement in Treatment
2026-05-19Press releaseMonopar Announces Publication of Phase 2 Study Demonstrating ALXN1840 Significantly Improves Copper Balance in Patients
Press releaseEarnings Release
2026-05-14Press releaseMonopar Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates
2026-05-14Press releasePDF
2026-04-19Press releaseMonopar Presents Phase 3 Data Showing Greater Neurologic Benefit with ALXN1840 vs SoC in Wilson Disease Patients with Ne
2026-03-27Press releaseMonopar Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Business Update
2026-03-16Presentationhttps://d1io3yog0oux5.cloudfront.net/_46c180b00471d92f154cbd1d20ad5d2c/monopartx/db/354/2994/pdf/MNPR+Corporate+Presentation+Mar+2026.pdf
2026-03-02Press releaseMonopar Expands Leadership Team with Appointment of Seasoned Biopharma Executive Susan Rodriguez as Chief Commercial and
2025-11-13Press releaseMonopar Therapeutics Reports Third Quarter 2025 Financial Results and Recent Developments
2025-11-09Press releaseMonopar Presents New Data and Analyses on Rapidly Improved Copper Balance in Wilson Disease Patients on Tiomolybdate Cho
2025-10-15Press releaseMonopar Announces Abstract Accepted for Oral Presentation at AASLD - The Liver Meeting® 2025
2025-09-23Press releaseMonopar Therapeutics Inc. Announces Pricing of $135 Million Underwritten Offering of Common Stock and Pre-Funded Warrant
2025-09-23Press releaseMonopar Announces Journal of Hepatology Publishes Physicians’ Letter to the Editor Demonstrating ALXN1840 Rapidly Improv
2025-09-14Press releaseMonopar to Present New Long-Term Neurological Efficacy and Safety Data for ALXN1840 in Wilson Disease at the 150th Ameri
2025-09-03Press releaseMonopar Announces Abstract Accepted with Distinction for Oral and Poster Presentations at the Upcoming American Neurolog
2025-08-12Press releaseMonopar Therapeutics Reports Second Quarter 2025 Financial Results and Recent Developments
2025-06-11Press releaseMonopar and EDNOC Announce Expanded Access Program for MNPR-101-Zr and MNPR-101-Lu in Advanced Cancers
2025-06-03Press releaseMonopar Therapeutics Announces Inclusion in the Russell 3000® and Russell 2000® Indexes

MNPR overview · MNPR earnings · MNPR financials · MNPR KPIs · MNPR documents · MNPR ownership · MNPR peers

Documents published by the company on its investor-relations site; summaries are model-written. Not personalized investment advice.